Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours

BACKGROUND: As a prelude to combination studies aimed at resistance reversal, this dose-escalation/dose-expansion study investigated the selective Src kinase inhibitor saracatinib (AZD0530) in combination with carboplatin and/or paclitaxel. METHODS: Patients with advanced solid tumours received sara...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaye, S, Aamdal, S, Jones, R, Freyer, G, Pujade-Lauraine, E, de Vries, E G E, Barriuso, J, Sandhu, S, Tan, D S-W, Hartog, V, Kuenen, B, Ruijter, R, Kristensen, G B, Nyakas, M, Barrett, S, Burke, W, Pietersma, D, Stuart, M, Emeribe, U, Boven, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364128/
https://www.ncbi.nlm.nih.gov/pubmed/22531637
http://dx.doi.org/10.1038/bjc.2012.158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364128/
https://www.ncbi.nlm.nih.gov/pubmed/22531637
http://dx.doi.org/10.1038/bjc.2012.158

Ejemplares similares